Lines blur as Big Pharma crosses borders into biotech

An article by CNNMoney breaks out a well-known theme in biotech: Big Pharma is attracted to the fast-growing field of biologics with its rising revenues and IP protected--still--from generic competition. That won't come as a surprise to anyone who's been following the string of licensing deals and acquisitions in the field. What's more interesting is the list of major new biotech facilities Big Pharma companies are building around the globe. That includes Bristol-Myers Squibb's biotech facility under construction in Massachusetts and Wyeth's $2.4 billion facility in Ireland. The article notes that analysts approve of biotech's protected status under current generic rules, and that even though it is likely that new rules will permit biogenerics, complicated manufacturing requirements for biotech drugs will make the field look much different than the knock-off game for traditional pharma.

- read the trend report from CNNMoney

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.